Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12370261-B2

Patent

Publication Date

2025-07-29

Expiration Date


Abstract

Provided herein are oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates, the chimeric peptides and peptide-oligonucleotide-conjugates comprising at least two cell-penetrating peptides, wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide. The oligoarginine peptide comprises the sequence [(RYzR)x] (SEQ ID NOs: 15-18), wherein R is arginine, Y is independently selected from aminohexanoic acid (X) or β-alanine (B). Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates comprising at least two cell-penetrating peptides, wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide described herein.

Core Innovation

The invention is a chimeric peptide–oligonucleotide conjugate, or a pharmaceutically acceptable salt thereof, in which an oligonucleotide is linked to multiple cell-penetrating peptides. The conjugate includes at least one amphipathic peptide and at least one oligoarginine peptide comprising a repeating arginine-containing sequence. The conjugate encompasses defined variations in linkers, terminal groups, oligonucleotides, and numbers of covalently linked peptides.

The disclosure indicates that chimeric conjugates improve exon-skipping readout compared with unconjugated PMO and single-cell-penetrating-peptide conjugates. Reported findings show that activity depends on covalent linkage, peptide identity, and peptide order, wherein separate administration of peptide conjugates fails to reproduce the benefit. Uptake studies implicate endocytosis, indicating distinct functional contributions of the respective peptides to cellular internalization and downstream activity.

Claims Coverage

The relevant claims identify one independent claim, claim 1, comprising four inventive features covering a Formula I chimeric peptide–oligonucleotide conjugate or pharmaceutically acceptable salt thereof.

Chimeric peptide–oligonucleotide conjugate

Claim 1 covers a Formula I conjugate, or a pharmaceutically acceptable salt thereof, comprising an oligonucleotide linked to 2, 3, 4, or 5 covalently linked cell-penetrating peptides.

Combination of amphipathic and oligoarginine peptides

At least one of the cell-penetrating peptides is an amphipathic peptide and at least one is an oligoarginine peptide.

Specified oligoarginine peptide sequence

The oligoarginine peptide comprises a repeating arginine-containing sequence [procedural detail omitted for safety] with defined spacer residues.

Covalent linkage of cell-penetrating peptides

The claim specifies two, three, four, or five cell-penetrating peptides covalently linked at the peptide termini.

The independent claim centers on a Formula I peptide–oligonucleotide conjugate or salt thereof, specifying multiple covalently linked cell-penetrating peptides combining amphipathic and oligoarginine peptides.

Stated Advantages

The disclosed chimeric conjugates improve exon-skipping and eGFP readout compared with unconjugated PMO and single-cell-penetrating-peptide conjugates, showing activity greater than additive expectations.

A PMO–penetratin–Bpep conjugate provides over 20-fold improvement versus PMO and about 70-fold fluorescence over untreated cells.

Documented Applications

Therapeutic applications include the treatment of neuromuscular and muscle diseases, including Duchenne muscular dystrophy.

Therapeutic applications include the treatment of viral infections and bacterial infections.

The conjugates are documented for use in cellular exon-skipping assays [procedural detail omitted for safety].

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.